|
1
|
Valery PC, Laversanne M and Bray F: Bone
cancer incidence by morphological subtype: A global assessment.
Cancer Causes Control. 26:1127–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McKenna WG, Barnes MM, Kinsella TJ,
Rosenberg SA, Lack EE and Glatstein E: Combined modality treatment
of adult soft tissue sarcomas of the head and neck. Int J Radiat
Oncol Biol Phys. 13:1127–1133. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Debebe Z and Rathmell WK: Ror2 as a
therapeutic target in cancer. Pharmacol Ther. 150:143–148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human microRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu X, Fortin K and Mourelatos Z:
MicroRNAs: Biogenesis and molecular functions. Brain Pathol.
18:113–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
11
|
Osaki M, Takeshita F, Sugimoto Y, Kosaka
N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T,
et al: MicroRNA-143 regulates human osteosarcoma metastasis by
regulating matrix metalloprotease-13 expression. Mol Ther.
19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boll K, Reiche K, Kasack K, Mörbt N,
Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn
F, et al: miR-130a, miR-203 and miR-205 jointly repress key
oncogenic pathways and are downregulated in prostate carcinoma.
Oncogene. 32:277–285. 2013. View Article : Google Scholar
|
|
14
|
Chen Z, Tang ZY, He Y, Liu LF, Li DJ and
Chen X: miRNA-205 is a candidate tumor suppressor that targets ZEB2
in renal cell carcinoma. Oncol Res Treat. 37:658–664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren D, Wei F, Hu L, Yang S, Wang C and
Yuan X: Phosphorylation of Runx2, induced by cyclic mechanical
tension via ERK1/2 pathway, contributes to osteodifferentiation of
human periodontal ligament fibroblasts. J Cell Physiol.
230:2426–2436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rashid H, Ma C, Chen H, Wang H, Hassan MQ,
Sinha K, de Crombrugghe B and Javed A: Sp7 and Runx2 molecular
complex synergistically regulate expression of target genes.
Connect Tissue Res. 55(Suppl 1): 83–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McGee-Lawrence ME, Carpio LR, Bradley EW,
Dudakovic A, Lian JB, van Wijnen AJ, Kakar S, Hsu W and Westendorf
JJ: Runx2 is required for early stages of endochondral bone
formation but delays final stages of bone repair in Axin2-deficient
mice. Bone. 66:277–286. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen H, Ghori-Javed FY, Rashid H, Adhami
MD, Serra R, Gutierrez SE and Javed A: Runx2 regulates endochondral
ossification through control of chondrocyte proliferation and
differentiation. J Bone Miner Res. 29:2653–2665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeng H and Xu X: RUNX2 RNA interference
inhibits the invasion of osteosarcoma. Oncol Lett. 9:2455–2458.
2015.PubMed/NCBI
|
|
20
|
Zhang R, Yan S, Wang J, Deng F, Guo Y, Li
Y, Fan M, Song Q, Liu H, Weng Y, et al: miR-30a regulates the
proliferation, migration, and invasion of human osteosarcoma by
targeting Runx2. Tumour Biol. 2015.
|
|
21
|
Ason B, Darnell DK, Wittbrodt B, Berezikov
E, Kloosterman WP, Wittbrodt J, Antin PB and Plasterk RH:
Differences in vertebrate microRNA expression. Proc Natl Acad Sci
USA. 103:14385–14389. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang M, Zhang P, Hu G, Xiao Z, Xu F,
Zhong T, Huang F, Kuang H and Zhang W: Relative expressions of
miR-205–5p, miR-205–3p, and miR-21 in tissues and serum of
non-small cell lung cancer patients. Mol Cell Biochem. 383:67–75.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Shan M, Liu Y, Yang F, Qi H, Zhou
L, Qiu L and Li Y: miR-205 suppresses the proliferative and
migratory capacity of human osteosarcoma Mg-63 cells by targeting
VEGFA. Onco Targets Ther. 8:2635–2642. 2015.PubMed/NCBI
|
|
24
|
Salajegheh A, Vosgha H, Md Rahman A, Amin
M, Smith RA and Lam AK: Modulatory role of miR-205 in angiogenesis
and progression of thyroid cancer. J Mol Endocrinol. 55:183–196.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hanna JA, Hahn L, Agarwal S and Rimm DL:
In situ measurement of miR-205 in malignant melanoma tissue
supports its role as a tumor suppressor microRNA. Lab Invest.
92:1390–1397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Y, Brenn T, Brown ER, Doherty V and
Melton DW: Differential expression of microRNAs during melanoma
progression: miR-200c, miR-205 and miR-211 are downregulated in
melanoma and act as tumour suppressors. Br J Cancer. 106:553–561.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Noguchi S, Iwasaki J, Kumazaki M, Mori T,
Maruo K, Sakai H, Yamada N, Shimada K, Naoe T, Kitade Y, et al:
Chemically modified synthetic microRNA-205 inhibits the growth of
melanoma cells in vitro and in vivo. Mol Ther. 21:1204–1211. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin C and Liang R: miR-205 promotes
epithelial-mesenchymal transition by targeting AKT signaling in
endometrial cancer cells. J Obstet Gynaecol Res. 41:1653–1660.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Niu K, Shen W, Zhang Y, Zhao Y and Lu Y:
miR-205 promotes motility of ovarian cancer cells via targeting
ZEB1. Gene. 574:330–336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li N, Luo D, Hu X, Luo W, Lei G, Wang Q,
Zhu T, Gu J, Lu Y and Zheng Q: RUNX2 and osteosarcoma. Anticancer
Agents Med Chem. 15:881–887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lucero CM, Vega OA, Osorio MM, Tapia JC,
Antonelli M, Stein GS, van Wijnen AJ and Galindo MA: The
cancer-related transcription factor Runx2 modulates cell
proliferation in human osteosarcoma cell lines. J Cell Physiol.
228:714–723. 2013. View Article : Google Scholar
|
|
32
|
Del Mare S and Aqeilan RI: Tumor
suppressor WWOX inhibits osteosarcoma metastasis by modulating
RUNX2 function. Sci Rep. 5:129592015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cohen-Solal KA, Boregowda RK and Lasfar A:
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving
force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Xie RL, Croce CM, Stein JL, Lian
JB, van Wijnen AJ and Stein GS: A program of microRNAs controls
osteogenic lineage progression by targeting transcription factor
Runx2. Proc Natl Acad Sci USA. 108:9863–9868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu N, Feng C, Jiang Y, Miao Q and Liu H:
Regulative effect of mir-205 on osteogenic differentiation of bone
mesenchymal stem cells (BMSCs): Possible role of SATB2/Runx2 and
ERK/MAPK pathway. Int J Mol Sci. 16:10491–10506. 2015. View Article : Google Scholar : PubMed/NCBI
|
